ReviewMolecular biology reports2026
Epigenetic regulation of adipogenesis on dental stem cells: a focus on histone modifications.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Dental stem cells (DSCs) have emerged as valuable tools in regenerative medicine due to their ability to differentiate into various cell types, including adipocytes. Although their adipogenic potential is generally described as modest or lower compared with mesenchymal stem cells from other sources, DSCs remain useful in vitro models for studying the mechanisms underlying adipose tissue formation. This review highlights recent advances in the epigenetic regulation of adipogenesis, including insights from histone modifications, particularly H3K9, which we contextualize within the broader landscape of epigenetic regulation in DSCs and other mesenchymal stem cells (MSCs). Additionally, the effects of epigenetic drugs are analyzed, and differences in adipogenic commitment among various types of DSCs are discussed. These findings underscore their importance as models for designing therapies targeting metabolic diseases.
Indexed as
Identifiers
41661344What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.